

Leading Oncology Company

Accelerates Drug Uptake by Driving Medication Adherence



THE CHALLENGE >>>



An oncology company initially enjoyed label favorability with the broader patient population, followed by label inferiority as competitors expanded labels without risk of adverse events (AE).

Initial dosing guidelines had led to:

High AE incidence | A shorter duration of therapy | Slower launch uptake



Medidata Acorn Al
Commercial Data Solutions
was providing the client's

commercial data management

solution, digesting 150+ data

sources daily.



Data indicated

Decreasing dosing size through titration resulted in a reduction in AEs.



The client wanted to identify physicians that were not titrating, to be able to deliver targeted dose adjustment messages from sales and medical teams.



This would lead to longer duration of therapy and accelerated adoption – maximizing medication adherence.



THE APPROACH >



Working with members of the client's commercial team, Acorn AI Commercial Data Solutions, jointly with <u>Acorn AI Labs</u>, analyzed rich patient level data, including claims, pharmacy, and laboratory tests to **identify physicians that were prescribing a high initial dose**.



Acorn Al identified physicians with patients that would benefit from a more tailored dosing regimen due to a higher incidence of AEs



Acorn Al set up automated daily alerts & messaging to those physicians by overlaying advanced analytics algorithms into the commercial data management system (STRATA®)



High potential physicians were targeted with dose adjustment messages from sales and medical teams.



THE IMPACT






Based on the automated triggers and dose adjustment messaging campaign, the proportion of physicians that titrated the initial dose increased from 4% to 62% amongst specialists and 11% to 37% amongst generalists over the course of a year.



This was a key driver in accelerating adoption and continued presence in the competitive landscape, as well as increasing field force targeting efficiency.

Initial Dose Strength for New Patients
Specialists vs Generalists breakdown by quarter



Evolution of dose strength of new patients by specialty. Data shows increasing adoption of dose titration over the course of 1.5 years.